[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623162":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Beijing Friendship Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Rectal Cancer ctDNA-MRD Detection Cohort",null,"This study is an exploratory study, with an expected enrollment of 60 patients diagnosed with stage II-III rectal cancer who are scheduled to undergo neoadjuvant therapy. The sample collection and testing procedures are as follows: Before neoadjuvant therapy: Baseline endoscopic biopsy tissue or paraffin sections:1.1 Two pieces of endoscopic biopsy tissue, approximately 2 mm in diameter, are collected and placed in tissue preservation tubes.1.2 Ten unstained tissue slides are prepared. Peripheral blood collection: 10 mL of blood is collected using cell-free DNA blood collection tubes for the following assays:① ctDNA-customized MRD high-depth sequencing;② ctDNA shallow whole-genome sequencing (sWGS) for monitoring copy number variation (CNV) profiles;③ Mitochondrial DNA (mtDNA) analysis. During neoadjuvant therapy (within 2 weeks after radiotherapy completion): Peripheral blood collection: 10 mL of blood is collected using cell-free DNA blood collection tubes for the followin",[13],"Diagnostic Test: Personalized ctDNA-MRD Detection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Personalized ctDNA-MRD Detection","This observational study involves collecting clinical data and biospecimens (peripheral blood and tissue samples) from participants at multiple timepoints. Personalized ctDNA-MRD detection technology, together with copy number variation and mtDNA profiling, is applied to analyze the samples. The primary goal is to predict neoadjuvant therapy efficacy by identifying biomarkers associated with key outcomes, such as tumor regression grade and pathological complete response rate. No experimental drugs or treatments are administered.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Yao Hongwei Professor, Doctoral Degree","CONTACT","13611015609","yaohongwei@ccmu.edu.cn",[27],{"facility":5,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Beijing","Beijing Municipality","100050","China","CN",{"type":35,"coordinates":36},"Point",[37,38],116.39723,39.9075,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":24,"phoneExt":10,"email":25},"HONGWEI YAO, MD",{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Yao Hongwei","Professor","100623162","application-and-exploration-of-personalized-ctdna-mrd-detection-technology-in-predicting-the-efficacy-of-neoadjuvant-therapy-for-rectal-cancer-100623162",false,"NCT07393048","Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant Therapy for Rectal Cancer","ctDNA-MRD-RC","Inclusion Criteria:\n\n* 1: Signed a written informed consent form and voluntarily participated in this study\n* 2: Aged 18-75 years, regardless of sex\n* 3: Histopathologically confirmed rectal adenocarcinoma\n* 4: Clinical stage II-III as assessed by MRI (according to the AJCC 8th edition)\n* 5: Distance from the lower tumor margin to the anal verge ≤10 cm\n* 6: Surgically resectable\n* 7: Able to swallow tablets normally\n* 8: ECOG PS 0-1\n* 9: No prior antitumor therapy for rectal cancer, including radiotherapy, chemotherapy, or surgery\n* 10: Scheduled to undergo surgical treatment after completion of neoadjuvant therapy\n* 11: No surgical contraindications\n* 12: Normal function of major organs, including: complete blood count, blood biochemistry, and coagulation function\n\nExclusion Criteria:\n\n* 1: History of allergy to monoclonal antibodies, any component of tislelizumab, or capecitabine\n* 2: Prior or ongoing receipt of any tumor-directed surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc\n* 3: Presence of any active autoimmune disease or history of autoimmune disease\n* 4: History of immunodeficiency, including a positive HIV test result, other acquired or congenital immunodeficiency disorders, or history of organ transplantation or allogeneic bone marrow transplantation\n* 5: Poorly controlled cardiac clinical symptoms or diseases, including but not limited to: heart failure of NYHA class II or above, unstable angina, myocardial infarction within the past year, or clinically significant supraventricular or ventricular arrhythmia that remains poorly controlled without or despite clinical intervention\n* 6: Diagnosis of another malignancy within 5 years prior to the first use of the study drug, except for malignancies with low risk of metastasis or death (5-year survival rate \\>90%), such as adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix, which may be considered for inclusion\n* 7: Pregnant or lactating women\n* 8: Other factors, as judged by the investigator, that may lead to premature termination of the study, such as other severe diseases (including psychiatric disorders) requiring concomitant treatment, alcohol abuse, drug abuse, family or social factors, or any condition that may affect the safety or compliance of the participant","ALL","18 Years","75 Years",{"count":58,"type":59},60,"ESTIMATED","OBSERVATIONAL","This study is a single-center, prospective, observational clinical trial enrolling patients with locally advanced rectal cancer (cT3-4aN0M0 and cT1-4aN1-2M0). By collecting tissue and blood samples at multiple timepoints, and integrating multi-omics data including ctDNA mutations, copy number variations, and mtDNA profiles, a multi-omics model will be constructed to predict the efficacy of neoadjuvant therapy for rectal cancer.",[63],"Locally Advanced Rectal Cancer (LARC)",[65,66,67,68,69],"ctDNA-MRD","Rectal Cancer","Neoadjuvant Therapy","Predicting the Efficacy","Detection Technology","2026-04-20",{"date":72,"type":73},"2026-04-21","ACTUAL",{"date":75,"type":73},"2026-02-15",{"date":77,"type":59},"2028-12-31",{"name":5,"class":6},1]